Detalhe da pesquisa
1.
A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adultsâ¯≥â¯60 years of age in Japan, South Korea, and Taiwan.
Vaccine
; 42(5): 1071-1077, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38267330
2.
A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of Age.
Pediatr Infect Dis J
; 43(6): 574-581, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38502894
3.
Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age.
Vaccine
; 41(45): 6625-6629, 2023 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37793976
4.
Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.
Vaccine
; 41(28): 4190-4198, 2023 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37244809